schizophrenia MedDRA version: 20.0 Level: PT Classification code 10039626 Term: Schizophrenia System Organ Class: 10037175 - Psychiatric disorders
Conditions
Interventions
Product Name: LY03004
Product Code: TEST
Pharmaceutical Form: Powder and solvent for prolonged-release suspension for injection
INN or Proposed INN: RISPERIDONE
CAS Number: 106266-06-2
Other descripti
Sponsors
Nanjing Luye Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Only subjects presenting the following criteria will be enrolled in the present study: [1] Male or female patients aged 18 to 65 years old, inclusive; [2] Patients must have a DSM-IV-TR diagnosis of schizophrenia based on the Mini-International Neuropsychiatric Interview (MINI). The duration of the illness must be at least 2 years prior to screening; [3] Patients must have an identified support person (e.g. family member, case worker, social worker) considered reliable by the investigator to help ensure compliance with study treatment and visits and to alert staff of any issues of concern; [4] Patients must have a stable place of residence for the 3 months prior to screening; [5] Patients must not have been either hospitalized for worsening of schizophrenic symptoms or judged by the investigator as having significant exacerbation of schizophrenic symptoms during the 3 months prior to screening; [6] Patients must be on a stable dose of oral antipsychotic medication(s) or on Risperidone depot 50 mg for at least 4 weeks prior to screening, AND clinically stable based on clinical assessments and having a Positive and Negative Syndrome Scale (PANSS) total score of =70 as well as a subtotal score of HATE (hostility, anxiety, tension and excitement) 35 IU/l in patients =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: [1] Patients with a primary and active DSM-IV-TR diagnosis other than schizophrenia; [2] Patients who received paliperidone palmitate within 10 months prior to screening. Oral risperidone tolerability test should be performed in those patients without documented evidence of tolerability to risperidone; [3] Patients who are non-responders to risperidone or paliperidone; [4] Patients who pose a significant risk of a suicide attempt based on history or the investigator’s judgment, or are at imminent risk of suicide or violent behavior based on the investigator’s clinical assessment; [5] Patients with a history of neuroleptic malignant syndrome or tardive dyskinesia, or a history of severe akathisia or extra-pyramidal reactions such as dystonia with previous use of risperidone or other neuroleptic treatments; [6] Patients with uncontrolled diabetes mellitus, or a HbA1c level =7%, or with diabetes mellitus requiring use of insulin. Patients with newly diagnosed Type 2 diabetes during the screening period are excluded; [7] Patients with a history of or who are currently diagnosed as having epilepsy or convulsion disorders; [8] Patients who have had electroconvulsive therapy within the past 2 months prior to screening; [9] Patients who used medication known to be a potent or moderate inhibitor of CYP 2D6 or a potent inducer of CYP 3A4 within 2 weeks or 5 PK half-lives, whichever is longer, prior to screening; [10] Patients with a history of an allergic reaction to risperidone or to the excipients of LY03004, or show an allergic reaction to oral risperidone tolerability test; [11] Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the exception of caffeine or nicotine in the past 6 months prior to screening, or test positive for a drug of abuse or alcohol at screening or baseline (except positive findings that can be accounted for by documented prescription use prescribed by a treating physician as a part of the treatment for the patient’s psychiatric illness); [12] Patients with a history of, or current clinically relevant cardiac arrhythmia, cardiovascular disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis; [13] Patients who have a history of malignancy within the past five years except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer; [14] Patients who have received a MAO inhibitor within 30 days prior to screening; [15] Female patients who are pregnant, or tested positive for pregnancy at screening, or are breastfeeding, or are of childbearing potential without adequate use of contraception; [16] Patients who have any uncontrolled, unstable clinically relevant medical condition (e.g. hepatic, renal, cardiovascular, endocrine, respiratory, hematologic, immunologic or cerebrovascular disease), or other medical condition, which in the judgment of the investigator would interfere with the subject's ability to participate in the study; [17] Patients with a QTcF interval greater than 450 msec for males and 470 msec for females, or other clinically significant ECG findings in the opinion of the investigator; [18] Patients who have any one of the following three conditions: (i) clinically significant liver dysfunction, (ii) HBsAg positive, (iii) a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels of > 2x upper limit of normal (ULN) range (if the ALT or AST levels are between 2x – 3x ULN in the first screening test and the elevation may
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the relative bioavailability of LY03004 compared to EU Risperdal® Consta® at 50 mg following multiple intramuscular injections at steady-state;;Secondary Objective: To evaluate the safety and tolerability of LY03004 following multiple dose administration in two different periods;Primary end point(s): Css-max, Ctrough and AUCss-tau of risperidone;Timepoint(s) of evaluation of this end point: After completion of the clinical part of the trial and database closure. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Css-max, Ctrough and AUCss-tau of 9-OH-risperidone and active moiety Additional endpoints are: Css-min, % Fluctuation, Tss-max of risperidone, 9-OH-risperidone and active moiety;Timepoint(s) of evaluation of this end point: After completion of the clinical part of the trial and database closure. | — |
Countries
Croatia
Contacts
Public ContactSponsor´s Project Manager
Luye Pharma Group, Ltd.
Outcome results
None listed